Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company's primary focus is on receiving contingent milestone payments from the sale of ONIVYDE to Ipsen S.A. in April 2017.
Operating without any ongoing research or development activities, Merrimack Pharmaceuticals utilizes external consultants for its operations and does not have any employees. The company's business model centers around its entitlement to milestone payments and strategic partnerships within the biopharmaceutical industry.
Generated from the website